Agency IQ

FEBRUARY 23, 2024

Additionally, this approach is generally no longer applicable to new treatments that are more targeted in their effects, such as immunotherapies and targeted small molecule therapies. LILLIAN SIU, an oncologist and clinical trialist at Toronto’s Princess Margaret Cancer Centre, was a panelist on the day’s second session. . …

Science 40

Science FDA Trials Clinical Pharmacology 40

Alta Sciences

AUGUST 28, 2023

The trial was performed at Altasciences’ clinical facility in Montréal. The Phase I trial was performed to evaluate safety, tolerability, and pharmacokinetics in a group of 80 healthy participants in a two-part, double-blind, placebo-controlled study. We are proud to support Ischemix in advancing this vital new therapy.”

Trials 40

Trials Treatment Clinical Pharmacology Pharmacokinetics 40

Agency IQ

DECEMBER 11, 2023

The side effects of some anticancer treatments can result in dose interruptions or de-escalations, or even outright discontinuation of an efficacious therapy. subsequent superior/inferior supportive care, lifestyle changes, or use of additional therapies).

FDA 40

FDA Science Clinical Trials Trials 40

Agency IQ

FEBRUARY 15, 2024

These topics include administrative, advanced manufacturing, the Animal Rule, antimicrobials, biosimilars, blood products, breakthrough devices, cell and gene therapy products, CGMP, clinical pharmacology, clinical trials, clinical/medical guidance, combination products, communication, compounding, cybersecurity, device software, digital health technologies, (..)

FDA 40

FDA Science Biosimilars Clinical Trials 40

The Anticancer Fund

JUNE 7, 2022

Ritonavir-Boosted Exposure of Kinase Inhibitors: an Open Label, Cross-over Pharmacokinetic Proof-of-Concept Trial with Erlotinib Published in Pharmaceutical Research This paper reports on an innovative way for using existing non-cancer drugs to reduce the dose and to potentially improve efficacy of approved expensive anticancer drugs.

Drugs 40

Drugs Clinical Trials Trials Treatment 40

The Pharma Data

FEBRUARY 8, 2021

1 Quality of life was comparable between treatment arms per Functional Assessment of Cancer Therapy–Prostate (FACT-P Total). v] ERLEADA ® is being studied in five Phase 3 clinical trials. . ‡ Thyroid replacement therapy, when clinically indicated, should be initiated or dose-adjusted. percent in the control arm.

Pharmaceutical Companies 52

Pharmaceutical Companies Treatment Clinical Trials Therapies 52

Drug Target Review

JANUARY 20, 2025

The oncology drug development landscape is evolving rapidly, driven by the deployment of targeted therapies in precision medicine and regulatory initiatives like the FDAs Project Optimus. Molecular factors Molecular markers, such as protein expression and signalling pathway activation, also guide therapy choices.

Clinical Trials 52

Clinical Trials Trials Drugs Drug Development 52

New Drug Approvals

APRIL 18, 2025

New Drug Therapy Approvals 2024 (PDF). Article ] Rosati G: Clinical pharmacology of iomeprol. Iomeron 300 mg J/ml-Infusionsflasche. Jump up to: a b “Novel Drug Approvals for 2024” U.S. Food and Drug Administration (FDA). 1 October 2024. Retrieved 29 November 2024. ^ Food and Drug Administration (FDA) (Report).

FDA 52

FDA Production FDA Approval Clinical Pharmacology 52

New Drug Approvals

APRIL 21, 2025

New Drug Therapy Approvals 2024 (PDF). Retrieved 20 December 2024. ^ “FDA approves BridgeBio Pharma’s Attruby to treat rare heart disease ATTR-CM” PMLiVE. 25 November 2024. Retrieved 25 November 2024. ^ Food and Drug Administration (FDA) (Report). January 2025. Archived from the original on 21 January 2025. 9 (1): 115129.

FDA Approval 62

FDA Approval FDA Production Treatment 62